Preventing primary liver cancer: How well are we faring towards a national hepatitis B strategy?

Medical Journal of Australia

Volumn 189, Issue 4, 2008, Pages 237-

  Awofeso, Niyi ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN;

AUSTRALIA; CANCER PREVENTION; CANCER RISK; HEPATITIS B; HUMAN; INCIDENCE; INDIGENOUS PEOPLE; LETTER; LIVER CANCER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MORTALITY; NONHUMAN; PREVALENCE; PRISONER; VACCINATION;

EID: 51349158772     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2008.tb02003.x     Document Type: Letter

References (6)

1. Robotin MC, George J, Supramaniam R, et al. Preventing primary liver cancer: how well are we faring towards a national hepatitis B strategy? Med J Aust 2008; 188: 363-365.
2. Butler T, Milner L. The 2001 New South Wales inmate health survey. Sydney: NSW Corrections Health Service, 2003.
3. Australian Government Department of Health and Ageing. Vaccination for our mob. Canberra: Commonwealth of Australia, 2006.
4. Amin J. Hepatitis B and C associated cancer and mortality: New South Wales, 1990-2002 [PhD thesis]. Sydney: University of New South Wales, 2006.
5. Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168-174.
6. Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaskan natives chronically infected with hepatitis B virus. Ann Intern Med 2001; 135: 759-768.